Lyra Therapeutics, Inc. Common Stock (LYRA) Stock Price

LYRAStock

$0.19−21.95%52W

Market Cap$337,227.58

P/E—

PEG Ratio—

Div yield—

Beta0.08

LYRA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-95.18%

Price vs S&P 500 (4W)-3.67%

VGM Score18.94

Book Value / Share (Quarterly)$1.00

P/TBV (Annual)1.87x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-33.61%

Cash Flow / Share (Quarterly)$-16.32

Price vs S&P 500 (YTD)-104.11%

Net Profit Margin (TTM)-7266.08%

EPS (TTM)$-19.31

10-Day Avg Trading Volume0.00M

EPS Excl Extra (TTM)$-19.31

Revenue Growth (5Y)4.35%

EPS (Annual)$-18.62

ROI (Annual)-805.89%

Net Profit Margin (5Y Avg)-7289.66%

Cash / Share (Quarterly)$8.95

Revenue Growth QoQ (YoY)-96.65%

ROA (Last FY)-80.09%

Revenue Growth TTM (YoY)-74.05%

EBITD / Share (TTM)$-19.69

ROE (5Y Avg)-220.19%

Operating Margin (TTM)-7794.47%

Cash Flow / Share (Annual)$-16.32

P/B Ratio0.21x

P/B Ratio (Quarterly)8.98x

Net Income / Employee (Annual)$-1,071,100

EV / Revenue (TTM)-39.08x

ROA (TTM)-61.30%

EPS Incl Extra (Annual)$-18.62

Current Ratio (Annual)1.71x

Quick Ratio (Quarterly)1.67x

3-Month Avg Trading Volume0.01M

52-Week Price Return-21.95%

Revenue / Employee (TTM)$14,700

Tangible BV / Share (Quarterly)$1.70

P/S Ratio (Annual)0.85x

Asset Turnover (Annual)0.01x

52-Week High$7.97

Operating Margin (5Y Avg)-7513.04%

EPS Excl Extra (Annual)$-18.62

CapEx CAGR (5Y)-42.08%

26-Week Price Return-85.27%

Quick Ratio (Annual)1.67x

13-Week Price Return-72.86%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.71x

Enterprise Value$-15.56M

Revenue / Share Growth (5Y)63.77%

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$14,700

Pretax Margin (Annual)-7263.32%

Cash / Share (Annual)$8.95

3-Month Return Std Dev8427.92%

Net Income / Employee (TTM)$-1,071,100

ROE (Last FY)-805.89%

EPS Basic Excl Extra (Annual)$-18.62

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-19.31

ROI (TTM)-411.98%

P/S Ratio (TTM)0.85x

Pretax Margin (5Y Avg)-7287.69%

Revenue / Share (Annual)$0.26

Tangible BV / Share (Annual)$2.54

Price vs S&P 500 (52W)-31.06%

Year-to-Date Return-93.83%

5-Day Price Return0.00%

EPS Normalized (Annual)$-18.62

ROA (5Y Avg)-78.88%

Net Profit Margin (Annual)-7266.08%

Month-to-Date Return533.33%

Cash Flow / Share (TTM)$-1.41

EBITD / Share (Annual)$-19.67

Operating Margin (Annual)-7794.47%

ROI (5Y Avg)-220.19%

EPS Basic Excl Extra (TTM)$-19.31

P/TBV (Quarterly)1.80x

P/B Ratio (Annual)1.17x

Pretax Margin (TTM)-7263.32%

Book Value / Share (Annual)$8.85

Price vs S&P 500 (13W)-75.54%

Beta0.08x

Revenue / Share (TTM)$0.22

ROE (TTM)-411.98%

52-Week Low$0.00

gGradeF

mGradeD

vgmGradeF

LYRA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Nov 12, 2025	-$4.07	-$3.40	+16.54%(+$0.67)
Q2 2025	Aug 12, 2025	-$4.78	-$5.22	-9.31%(-$0.44)
Q1 2025	May 6, 2025	-$6.83	-$6.50	+4.88%(+$0.33)
Q4 2024	Mar 13, 2025	-$6.50	-$7.09	-9.15%(-$0.59)

LYRA Analyst Recommendations

Apr 2026

May 2026

Jun 2026

Jul 2026

2.17

Industry Peers — Surgical & Medical Instruments(142)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
LYRALyra Therapeutics, Inc. Common Stock	—	F	D	0.8x	4.3%	—	-7794.5%	$0.19
SYKStryker Corporation	C	B	C	4.4x	11.8%	65.3%	21.3%	$294.66
MMM3M Company	C	D	B	3.4x	-5.0%	39.4%	18.4%	$164.75
BSXBoston Scientific Corp.	C	B	C	3.1x	15.2%	69.5%	19.8%	$44.39
BDXBecton, Dickinson and Co.	B	D	A	2.5x	6.3%	46.7%	9.6%	$191.75
MDLNMedline Inc. Class A common stock	C	D	C	1.6x	—	26.2%	6.0%	$35.96
RMDResMed Inc.	C	C	B	5.9x	12.1%	61.1%	33.4%	$238.97
DXCMDexCom, Inc.	C	B	B	6.5x	19.3%	64.3%	22.9%	$86.04
WSTWest Pharmaceutical Services, Inc.	D	C	A	8.5x	7.4%	36.8%	20.4%	$384.02
SOLVSolventum Corporation	C	C	B	1.8x	—	54.8%	23.9%	$85.81
BAXBaxter International Inc.	B	D	B	1.1x	-0.8%	30.7%	-2.3%	$25.28
PENPenumbra, Inc.	F	C	B	8.4x	20.2%	67.8%	12.4%	$320.86
GMEDGLOBUS MEDICAL INC	B	B	B	3.3x	30.1%	68.5%	20.6%	$76.71
PODDInsulet Corporation	C	A	C	3.2x	24.5%	71.1%	16.9%	$141.10
GKOSGlaukos Corporation	F	A	B	15.9x	17.7%	79.1%	-31.6%	$164.84
TFXTeleflex Incorporated	B	F	B	2.1x	-4.7%	53.8%	-11.7%	$130.43
HAEHaemonetics Corporation	C	C	A	4.0x	8.9%	59.1%	11.9%	$118.28
MMSIMerit Medical Systems Inc	C	B	B	3.4x	9.5%	49.5%	12.8%	$89.20
STVNStevanato Group S.p.A.	D	C	C	3.7x	12.4%	29.9%	16.4%	$18.90
MMEDMiniMed Group, Inc. Common Stock	—	—	B	—	—	—	—	$17.49
HTFLHeartflow, Inc. Common Stock	F	A	A	19.8x	—	80.1%	-40.8%	$48.29
ICUIICU Medical Inc	C	D	B	1.9x	11.9%	39.1%	3.5%	$162.99
IRTCiRhythm Holdings, Inc. Common Stock	D	B	C	4.3x	23.0%	71.5%	-3.0%	$108.66
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	2725.9x	—	0.3%	-7007.8%	$44.43
ATRCAtriCure, Inc.	D	B	A	5.0x	20.9%	76.3%	2.3%	$56.07
UFPTUFP Technologies Inc	C	B	A	3.6x	27.4%	28.5%	15.3%	$291.67
INSPInspire Medical Systems, Inc.	B	B	B	2.2x	51.2%	86.1%	6.0%	$68.79
LMATLeMaitre Vascular, Inc.	C	B	C	7.0x	14.0%	72.9%	29.5%	$80.82
NVCRNovoCure Limited Ordinary Shares	D	C	C	2.3x	5.8%	76.1%	-22.1%	$14.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	15.2x	—	53.9%	-140.4%	$27.24
ATECAlphatec Holdings, Inc.	D	B	C	2.0x	39.5%	70.8%	-7.5%	$10.46
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	B	—	—	—	—	$12.29
TNDMTandem Diabetes Care, Inc.	D	C	C	1.1x	15.3%	56.0%	-4.4%	$16.24
IRMDiRadimed Corporation	D	B	B	13.1x	21.4%	75.9%	31.9%	$88.27
AORTArtivion, Inc.	C	C	C	2.3x	11.8%	64.4%	2.9%	$21.78
IARTIntegra LifeSciences Holdings	B	F	C	0.6x	3.6%	57.2%	4.0%	$13.21
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	3.0x	109.0%	64.2%	-33.9%	$17.57
BVSBioventus Inc. Class A Common Stock	B	C	A	1.9x	12.1%	68.7%	10.0%	$13.30
BBNXBeta Bionics, Inc. Common Stock	D	A	C	7.4x	—	58.3%	-69.8%	$16.35
SIBNSI-BONE, Inc. Common Stock	D	B	B	4.1x	22.3%	79.5%	-8.3%	$19.68
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	—	—	—	—	$24.00
MDXGMiMedx Group, Inc	C	D	C	1.8x	11.0%	78.8%	2.5%	$4.43
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	2.3x	27.2%	73.7%	-11.9%	$21.95
TCMDTactile Systems Technology, Inc.	B	B	B	1.5x	12.0%	51.9%	10.0%	$22.52
SSIISS Innovations International Inc. Common Stock	F	A	D	9.7x	—	47.6%	-16.2%	$2.53
DCTHDelcath Systems Inc	D	C	B	5.1x	120.1%	87.0%	-1.9%	$14.08
ANGOAngioDynamics, Inc.	C	D	C	1.5x	1.9%	55.6%	-11.2%	$11.24
BWAYBrainsway Ltd. American Depositary Shares	D	B	B	9.5x	12.2%	74.9%	5.8%	$11.44
SGHTSight Sciences, Inc. Common Stock	D	B	A	5.5x	22.9%	88.4%	-33.4%	$8.28
CERSCerus Corp	D	C	C	1.8x	15.4%	57.2%	-0.7%	$2.18
NPCENeuropace, Inc. Common Stock	D	C	C	4.3x	19.4%	79.6%	-15.3%	$12.24

About Lyra Therapeutics, Inc. Common Stock

Lyra Therapeutics is a clinical-stage biopharmaceutical company developing innovative drug delivery solutions for ear, nose, and throat (ENT) diseases. The company's lead product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices administered in brief, non-invasive in-office procedures to deliver continuous therapy directly to the sinonasal passages for chronic rhinosinusitis. This localized delivery approach aims to provide therapeutic benefits while minimizing systemic exposure.